Aura Corp (AURA): Price-to-Projected Revenue Ratio

Corporate emblem and logo of Aura Corp (AURA)

Aura Biosciences, Inc. (AURA) aims to monopolize the ocular melanoma treatment market through large-scale trials of belzupacap sarotalocan. The current forward P/S ratio reflects market expectations, where characterizes this valuation metric. The development of targeted methods is being conducted in collaboration with leading ophthalmology centers. Preparations for the regulatory audit are evidenced by high activity within the R&D pipeline for the creation of viral conjugates.

Aura Biosciences Inc - AURA Forward P/S Multiple (period 07/04/2022 - 11/18/2026)

Aura Biosciences, Inc. (AURA) - metric breakdowns and financial figures

Comprehensive company analysis:AURA (aurabiosciences.com)
Product sample of Aura Corp

An investor determines an asset's margin of safety by comparing current market capitalization with expected earnings, which allows for the identification of whether a business is overbought or undervalued. The integration of strict ESG standards into the oncological developments of Aura Biosciences, Inc. (AURA) influences the projected price-to-sales ratio, reflecting the market value of an ethical approach to medicine within the high-risk biotechnology sector.

Competitor analysis

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple